Factor IX Deficient Plasma

INTENDED USE

George King Factor IX Deficient Plasma is citrated human plasma derived from congenital Factor IX Deficient donors and intended for use as a substrate in the qualitative determination of Factor IX activity based on the activated partial thromboplastin time (APTT) assay. For in vitro diagnostic use only.

SUMMARY AND PRINCIPLE:

Hemophilia B is characterized by deficiency in factor IX clotting activity that results in prolonged oozing after injuries, tooth extractions, or surgery, and delayed or recurrent bleeding prior to complete wound healing. Also termed Christmas disease, hemophilia B is an X-linked inherited bleeding disorder, usually manifested in males and transmitted by females when they carry the abnormality on the X chromosome. FIX deficiency is 4-6 times less prevalent than factor VIII (FVIII) deficiency. Mutations in human coagulation factor IX that cause hemophilia B may be classified as severe, moderately severe and mild based on the plasma levels of factor IX among affected individuals (< 1%, 2-5%, 6-30%, respectively).

Citrated patient plasma is diluted, added to a factor IX-deficient substrate and an APTT is performed. The % factor activity is interpolated using a reference curve with the same dilutions of a calibrator plasma and FIX-deficient substrate.

REAGENT

George King Factor IX deficient plasma (9890) - no buffers or stabilizers have been added.

WARNINGS

Each individual donor plasma used in these products has been tested and found to be non-reactive for the presence of HBsAg and antibody to HIV. Anti-HCV positive, NAT negative donors have been identified. Because no known test method can offer complete assurance that these or other infectious agents are absent, this product should be handled at the Biosafety Level 2 as recommended for any human blood-based product in the Centers for Disease Control National Institutes of Health manual ‘Biosafety in Microbiological and Biomedical Laboratories,’ 1999.

PREPARATION

Place vial in 37°C water bath until plasma is thawed. Exact time is determined by volume of plasma in vial - approximately 2-6 minutes for 1.0 mL vials. Mix gently and keep on cool until ready to use. Plasma must be discarded once thawed and used. DO NOT REFREEZE.

STORAGE and STABILITY:

Recommended storage: -70°C or below. Stability for FIX deficient plasma is 3 years from the date of manufacture. Plasmas must remain frozen and will be stable until expiration date shown on vial. Remove plasma from dry ice packaging upon receipt and place in freezer overnight before use. (Self-defrost freezer not recommended). Plasma is stable for 4 hours after being thawed when kept at refrigerated temperatures, and stable for 4 hours at room temperature.

PROCEDURE

Plasmas should be used as indicated by specific assay direction inserts for instrument and reagent system being used. See instrument manual and reagent direction insert for specific instructions regarding specimen preparation, procedure and limitations.

REAGENTS AND MATERIALS REQUIRED, NOT PROVIDED:

- APTT Reagent / CaCl2
- Quality Control (2 levels) Coagulation Instrument
- Plastic tubes / pipets

QUALITY CONTROL:

Two levels of quality control (normal and abnormal) should be performed each 8 hours of operation in accordance with good laboratory practice. Each laboratory should establish its own mean and standard deviation and should establish a quality control program to monitor laboratory testing.

SPECIMEN COLLECTION AND PREPARATION:

Nine parts freshly drawn venous blood is collected into one part trisodium citrate. Refer to CLSI Document H21-A5 for further instructions on specimen collection and handling.

EXPECTED VALUES

George King Factor IX Deficient Plasma has been tested at 41% factor activity. All other coagulation factors have been tested and found to be within the normal range.

NORMAL REFERENCE RANGE

The normal range for FIX activity in adults is 50-150% according to literature. However, each laboratory should determine its own normal range.

PERFORMANCE CHARACTERISTICS

Precision was assessed in-house on two lots of GK FIX deficient plasma following CLSI EPS guidelines. Multiple FIX assays (n=80) were performed over 20 non-consecutive days on the ACL TOP 500 using a specific lot of SynthFix and GK PEP (normal), GK B-FACT (borderline) and GK A-FACT (low abnormal) controls.

Acceptable (CV% < 10%) when using an optical instrument.

All studies were performed using an optical instrument. Validation studies would need to be performed by the end user if utilizing an instrument other than optical, i.e. clotting, chromogenic and immunologic test methods.

References:
1. Schwartz R, Besa E. Factor IX Deficiency Medscape

MGEOGE KING BIO-MEDICAL, INC.
11171 W 112th St
Overland Park KS 66210-2782 USA
913-469-5464 800-255-5108
Fax: 913-469-0871
www.kingbiomed.com plasma@kingbiomed.com

Revised 02/2017